融合-话题@MedSci

#融合#

253篇内容 | 1815人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1525554, encodeId=b085152555420, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Blood：GNAO1突变和ETV6-RUNX1融合变异促进白血病发生的协同作用, objectType=article, longId=200932, objectId=ded52009329b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ded52009329b, replyNumber=0, likeNumber=43, createdTime=2020-09-21, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ded52009329b, moduleTitle=Blood：GNAO1突变和ETV6-RUNX1融合变异促进白血病发生的协同作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ded52009329b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525553, encodeId=0eb51525553ad, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, objectType=article, longId=200381, objectId=9ed320038179, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed320038179, replyNumber=0, likeNumber=41, createdTime=2020-09-09, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed320038179, moduleTitle=FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed320038179)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525552, encodeId=ad62152555215, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Blood：融合转录因子PML/RARα在急性早幼粒细胞白血病进展中的作用, objectType=article, longId=200283, objectId=ee8e20028339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee8e20028339, replyNumber=0, likeNumber=25, createdTime=2020-09-06, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee8e20028339, moduleTitle=Blood：融合转录因子PML/RARα在急性早幼粒细胞白血病进展中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee8e20028339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525551, encodeId=bfb21525551cf, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, objectType=article, longId=199973, objectId=8ec51999e38c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ec51999e38c, replyNumber=0, likeNumber=32, createdTime=2020-08-29, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ec51999e38c, moduleTitle=NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ec51999e38c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525550, encodeId=cc2015255507b, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Prostate Cancer P D：较少的经尿道系统活检核心能否与磁共振成像/超声融合活检具有相同的前列腺癌检出率？, objectType=article, longId=199387, objectId=fe2a19938e9c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2a19938e9c, replyNumber=0, likeNumber=31, createdTime=2020-08-15, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2a19938e9c, moduleTitle=Prostate Cancer P D：较少的经尿道系统活检核心能否与磁共振成像/超声融合活检具有相同的前列腺癌检出率？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe2a19938e9c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525549, encodeId=0f4915255499e, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=PLOS computational biology：AI融合基因组学研究预测阿尔茨海默病的早期分子标记, objectType=article, longId=199158, objectId=973d19915878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=973d19915878, replyNumber=0, likeNumber=30, createdTime=2020-08-12, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=973d19915878, moduleTitle=PLOS computational biology：AI融合基因组学研究预测阿尔茨海默病的早期分子标记, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=973d19915878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525548, encodeId=063f152554892, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, objectType=article, longId=198676, objectId=870a1986e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870a1986e628, replyNumber=0, likeNumber=51, createdTime=2020-08-05, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870a1986e628, moduleTitle=Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870a1986e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525547, encodeId=10d3152554e2d, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后, objectType=article, longId=196602, objectId=6b09196602cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b09196602cb, replyNumber=0, likeNumber=16, createdTime=2020-06-29, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b09196602cb, moduleTitle=Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b09196602cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525546, encodeId=d81515255467e, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, objectType=article, longId=196520, objectId=4e2c19652009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c19652009, replyNumber=0, likeNumber=45, createdTime=2020-06-27, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c19652009, moduleTitle=又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e2c19652009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525545, encodeId=accd152554538, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=ARCH PATHOL LAB MED：肺腺癌患者检测ROS1免疫组化与ROS1融合状态意义？, objectType=article, longId=196458, objectId=0cdf19645858, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cdf19645858, replyNumber=0, likeNumber=36, createdTime=2020-06-26, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cdf19645858, moduleTitle=ARCH PATHOL LAB MED：肺腺癌患者检测ROS1免疫组化与ROS1融合状态意义？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cdf19645858)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525544, encodeId=2b19152554424, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, objectType=article, longId=195490, objectId=a38e195490b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e195490b9, replyNumber=0, likeNumber=19, createdTime=2020-06-10, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e195490b9, moduleTitle=EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a38e195490b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525543, encodeId=4507152554300, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市, objectType=article, longId=194691, objectId=1a6f1946914b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a6f1946914b, replyNumber=0, likeNumber=0, createdTime=2020-05-26, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a6f1946914b, moduleTitle=NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a6f1946914b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525542, encodeId=37de152554264, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Sci Adv：杜克大学华人团队发现细胞融合及胎盘发育的新机制, objectType=article, longId=194495, objectId=bc71194495c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc71194495c7, replyNumber=0, likeNumber=57, createdTime=2020-05-22, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc71194495c7, moduleTitle=Sci Adv：杜克大学华人团队发现细胞融合及胎盘发育的新机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc71194495c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525541, encodeId=2828152554102, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=FDA批准了针对RET基因突变或融合癌症的药物--Retevmo, objectType=article, longId=193857, objectId=f26b19385e5c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f26b19385e5c, replyNumber=0, likeNumber=0, createdTime=2020-05-11, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f26b19385e5c, moduleTitle=FDA批准了针对RET基因突变或融合癌症的药物--Retevmo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f26b19385e5c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525540, encodeId=59e8152554085, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=Blood：CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点, objectType=article, longId=193458, objectId=f73b193458ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f73b193458ee, replyNumber=0, likeNumber=42, createdTime=2020-05-05, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f73b193458ee, moduleTitle=Blood：CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f73b193458ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525539, encodeId=7b9d1525539f6, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析, objectType=article, longId=193161, objectId=31991931618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31991931618c, replyNumber=0, likeNumber=34, createdTime=2020-05-01, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31991931618c, moduleTitle=AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31991931618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525538, encodeId=04e1152553819, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=J Endod：上下颌经牙髓治疗的融合根管磨牙与根尖周损伤之间的联系, objectType=article, longId=193029, objectId=48a2193029dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48a2193029dd, replyNumber=0, likeNumber=34, createdTime=2020-04-28, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48a2193029dd, moduleTitle=J Endod：上下颌经牙髓治疗的融合根管磨牙与根尖周损伤之间的联系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48a2193029dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525537, encodeId=4b4b152553e9c, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=浙江引进首台数字化乳腺断层融合摄影检出率提高超30%, objectType=article, longId=192805, objectId=39cd192805a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39cd192805a4, replyNumber=0, likeNumber=25, createdTime=2020-04-24, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39cd192805a4, moduleTitle=浙江引进首台数字化乳腺断层融合摄影检出率提高超30%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39cd192805a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525536, encodeId=ef6d15255362f, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, objectType=article, longId=192797, objectId=6bd8192e9745, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bd8192e9745, replyNumber=0, likeNumber=32, createdTime=2020-04-24, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bd8192e9745, moduleTitle=英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bd8192e9745)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1525535, encodeId=9930152553546, content=<a href='/topic/show?id=08548885835' target=_blank style='color:#2F92EE;'>#融合#</a>, objectTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, objectType=article, longId=192487, objectId=54e819248eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54e819248eed, replyNumber=0, likeNumber=0, createdTime=2020-04-20, rootId=0, userName=licz0427, userId=08a911636812, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54e819248eed, moduleTitle=获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54e819248eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

融合

2020-05-29

licz0427 (审核中...)

前往app查看评论内容

#融合#

Blood：GNAO1突变和ETV6-RUNX1融合变异促进白血病发生的协同作用

2020-09-21

licz0427 (审核中...)

前往app查看评论内容

#融合#

FDA批准Gavreto（pralsetinib）治疗转移性RET融合阳性非小细胞肺癌

2020-09-09

licz0427 (审核中...)

前往app查看评论内容

#融合#

Blood：融合转录因子PML/RARα在急性早幼粒细胞白血病进展中的作用

2020-09-06

licz0427 (审核中...)

前往app查看评论内容

#融合#

NEJM：Selpercatinib用于RET融合阳性非小细胞肺癌患者的治疗

2020-08-29

licz0427 (审核中...)

前往app查看评论内容

#融合#

Prostate Cancer P D：较少的经尿道系统活检核心能否与磁共振成像/超声融合活检具有相同的前列腺癌检出率？

2020-08-15

licz0427 (审核中...)

前往app查看评论内容

#融合#

PLOS computational biology：AI融合基因组学研究预测阿尔茨海默病的早期分子标记

2020-08-12

licz0427 (审核中...)

前往app查看评论内容

#融合#

Rozlytrek（entrectinib）治疗NTRK基因融合的实体瘤：已获欧盟批准

2020-08-05

licz0427 (审核中...)

前往app查看评论内容

#融合#

Sci Rep：携带RET融合基因的女性肺癌患者独特的遗传特征和临床预后

2020-06-29

licz0427 (审核中...)

前往app查看评论内容

#融合#

又一“广谱”抗癌药获批：NICE批准Rozlytrek治疗NTRK基因融合的所有实体瘤

2020-06-27

licz0427 (审核中...)

前往app查看评论内容

#融合#

ARCH PATHOL LAB MED：肺腺癌患者检测ROS1免疫组化与ROS1融合状态意义？

2020-06-26

licz0427 (审核中...)

前往app查看评论内容

#融合#

EULAR 2020：头对头III期研究证实AbbVie的JAK1抑制剂upadacitinib治疗类风湿关节炎，优于CTLA-4-Fc融合蛋白abatacept

2020-06-10

licz0427 (审核中...)

前往app查看评论内容

#融合#

NTRK基因融合性肿瘤的治疗：larotrectinib即将在日本上市

2020-05-26

licz0427 (审核中...)

前往app查看评论内容

#融合#

Sci Adv：杜克大学华人团队发现细胞融合及胎盘发育的新机制

2020-05-22

licz0427 (审核中...)

前往app查看评论内容

#融合#

FDA批准了针对RET基因突变或融合癌症的药物--Retevmo

2020-05-11

licz0427 (审核中...)

前往app查看评论内容

#融合#

Blood：CDK6是携带NUP98融合蛋白的急性髓系白血病的一个新的潜在治疗靶点

2020-05-05

licz0427 (审核中...)

前往app查看评论内容

#融合#

AACR 2020：拉罗替尼治疗TRK融合肿瘤的亚组分析

2020-05-01

licz0427 (审核中...)

前往app查看评论内容

#融合#

J Endod：上下颌经牙髓治疗的融合根管磨牙与根尖周损伤之间的联系

2020-04-28

licz0427 (审核中...)

前往app查看评论内容

#融合#

浙江引进首台数字化乳腺断层融合摄影检出率提高超30%

2020-04-24

licz0427 (审核中...)

前往app查看评论内容

#融合#

英国NICE推荐TRK抑制剂VITRAKVI（larotrectinib），用于NTRK基因融合阳性的实体瘤

2020-04-24

licz0427 (审核中...)

前往app查看评论内容

#融合#

获得1亿美元融资后，荣昌生物的融合蛋白TACI-Fc治疗红斑狼疮获得FDA快速通道指定

2020-04-20

科室
- - 订阅+
  - 更多科室
工具
服务